Page last updated: 2024-11-06

promethazine sulfoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

promethazine sulfoxide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID63032
CHEMBL ID3544889
CHEBI ID184090
SCHEMBL ID3320530
MeSH IDM0269906

Synonyms (29)

Synonym
romergan sulfoxide
promethazine 5-oxide
promethazine 5-sulfoxide
promethazine sulfoxide
n,n-dimethyl-1-(5-oxophenothiazin-10-yl)propan-2-amine
CHEBI:184090
10-(2-(dimethylamino)propyl)-10h-phenothiazine 5-oxide
AKOS016007600
7640-51-9
10h-phenothiazine-10-ethanamine, n,n,alpha-trimethyl-, 5-oxide
g44a4px06u ,
unii-g44a4px06u
n,n,alpha-trimethyl-10h-phenothiazine-10-ethanamine 5-oxide
FT-0674049
SCHEMBL3320530
CHEMBL3544889
10h-phenothiazine-10-ethanamine, n,n,.alpha.-trimethyl-, 5-oxide
promethazine sulphoxide 1.0 mg/ml in methanol
(2rs)-n,n-dimethyl-1-(10h-phenothiazin-10-yl)propan-2-amine s-oxide (promethazine sulphoxide)
promethazine sulphoxide
(2rs)-n,n-dimethyl-1-(10h-phenothiazin-10-yl)propan-2-amine s-oxide; promethazine hydrochloride imp. d (ep); promethazine sulphoxide; promethazine hydrochloride impurity d; promethazine impurity d
10-(2-(dimethylamino)propyl)-10h-phenothiazine5-oxide
DTXSID50997774
10-[2-(dimethylamino)propyl]-5lambda~4~-phenothiazin-5(10h)-one
Q27278710
(2rs)-n,n-dimethyl-1-(10h-phenothiazin-10-yl)propan-2-amine s-oxide
promethazine hydrochloride impurity d [ep impurity]
n-(2-(dimethylamino)propyl)phenothiazine s-oxide
promethazine sulfoxide, (+/-)-

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenothiazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.07 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index32.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]